Background The COVID-19 pandemic presents two main concerns for patients with myasthenia gravis (MG); chronic immunosuppression may put them at greater risk, and some proposed treatments for COVID-19 could cause MG exacerbation. Case description We present three patients with generalized seropositive MG who developed COVID-19. All patients had a favorable outcome, with only one patient experiencing exacerbation. In this case, exacerbation began before COVID-19; she required ICU admission, non-invasive ventilatory support, and received hydroxychloroquine, lopinavir and ritonavir which were well tolerated. One patient received IVIG in place of scheduled plasma exchange. Conclusion Outcome was favorable in all cases despite immunosuppressive therapy, use of experimental COVID-19 medication and switching of plasma exchange for IVIG.

中文翻译：

---

3 名重症肌无力合并 COVID-19 患者的描述


背景 COVID-19 大流行给重症肌无力 (MG) 患者带来了两个主要问题：慢性免疫抑制可能会使他们面临更大的风险，并且一些针对 COVID-19 的拟议治疗可能会导致 MG 恶化。病例描述 我们介绍了三名患有 COVID-19 的全身性血清阳性 MG 患者。所有患者均获得良好结果，只有一名患者病情恶化。在本例中，病情恶化发生在 COVID-19 之前；她需要入住 ICU，接受无创通气支持，并接受了耐受性良好的羟氯喹、洛匹那韦和利托那韦。一名患者接受 IVIG 代替定期血浆置换。结论 尽管进行了免疫抑制治疗、使用实验性 COVID-19 药物以及将血浆置换改为 IVIG，但所有病例的结果均良好。